Table 5.
Statistically Significant Reasons for Treatment Discontinuation – Antimuscarinic versus Tolterodine IR/ER or Oxybutynin IR
| Outcome | Total Comparisons/Studies | All Studies | Oxybutynin ER | Solifenacin | Total Studies | Oxybutynin ER | Total Studies | Fesoterodine |
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)(Minassian et al., 2007) | RR (95% CI)(Herschorn et al., 2011) | RR (95% CI)(Sand et al., 2004) | RR (95% CI)(DuBeau et al., 2012) | ||||
|
| ||||||||
| Versus Oxybutynin IR | Versus Tolterodine IR | Versus Tolterodine ER | ||||||
| AEs | 1 | 0.40 (0.15–1.12) | 0.40 (0.15–1.12) | 0.40 (0.15–1.12) | 1 | 1.08 (0.52–2.23) | 1 | 3.15
(1.81–5.49) NNH=17.0 |
*
I2 >25%;
†
Adverse Event noted in Study but 0 count,
AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; NNH = Number Needed to Harm; RR= rate ratio